About Yanyang Bio
Yanyang Bio is a Healthcare company founded in 2019. It operates as a microbiome-based therapeutics for bacterial diseases are developed through high-throughput screening. Yanyang Bio has raised $14.8 million across 1 funding round from investors including Dalton Venture and Shenzhen Chuangdong Investment. Its focus areas include Life Sciences, Microbiome Therapeutics, Phage Therapy and Infectious Diseases.
Company details
Yanyang Bio was founded in 2019 in the biotechnology sector. Microbiome-based therapeutics for bacterial diseases are developed by the company. Live bacteriophage drugs are produced using high-throughput screening of anaerobic microorganisms, along with conservation methods and preparation of active bacteria. Focus is placed on treatments for bacterial infections, with operations centered on innovative drug development processes. No specific geographic location is indicated for the companys activities.
- SectorsHealthcare
- Total Equity Funding$14.8M (USD)
in 1 rounds
- Latest Funding Round$14.8M (USD), Series A
Aug 2022
- InvestorsDalton Venture
& 1 more
Funding Insights of Yanyang Bio
Yanyang Bio has successfully raised a total of $14.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $14.8 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.8M
- Total Rounds 1
- Last Round Series A — $14.8M
- First Round $14.8M
(Aug 2022)
- Investors Count 2
All 1 funding rounds of Yanyang Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $14.8M | Series A | – | Dalton Venture |
2 investors in total: 2 institutional.
Investors in Yanyang Bio
Yanyang Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Dalton Venture and Shenzhen Chuangdong Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical industry focused VC firm | – | daltonventure.cn | Shanghai, China | |
- | – | cdfcn.com | - |
Investor details for Yanyang Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Yanyang Bio
2 dated milestones of Yanyang Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Yanyang Bio is founded.
- Funding First funding round of $14.8M.
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as Yanyang Bio (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Yanyang Bio
Yanyang Bio was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Yanyang Bio is a funded company, having raised a total of $14.8M across 1 funding round to date. The company's 1st funding round was a Series A of $14.8M, raised on Aug 2022.
Yanyang Bio was founded in 2019 in the biotechnology sector. Microbiome-based therapeutics for bacterial diseases are developed by the company. Live bacteriophage drugs are produced using high-throughput screening of anaerobic microorganisms, along with conservation methods and preparation of active bacteria. Focus is placed on treatments for bacterial infections, with operations centered on innovative drug development processes. No specific geographic location is indicated for the companys activities.
Yanyang Bio has 2 investors. Key investors include Dalton Venture, and Shenzhen Chuangdong Investment.